コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 sociated with increased risk of developing a schizophrenia spectrum disorder.
2 s (EIS) among individuals with first-episode schizophrenia spectrum disorder.
3 iated with an increased risk of developing a schizophrenia spectrum disorder.
4 , leaving them at high risk for developing a schizophrenia spectrum disorder.
5 olescence that may serve as risk factors for schizophrenia spectrum disorders.
6 gyrus and may be a vulnerability marker for schizophrenia spectrum disorders.
7 rnal age and risk of adult schizophrenia and schizophrenia spectrum disorders.
8 3-6) for bipolar disorders; and 4% (3-5) for schizophrenia spectrum disorders.
9 nd between perimenopause and first onsets of schizophrenia spectrum disorders.
10 ia is a distressing and prevalent symptom in schizophrenia spectrum disorders.
11 about a fifth of real-world individuals with schizophrenia spectrum disorders.
12 trol and weight outcomes in individuals with schizophrenia spectrum disorders.
13 ebellar gray matter volume has been found in schizophrenia spectrum disorders.
14 sion and recovery are rare among people with schizophrenia spectrum disorders.
15 outcome was monthly counts of ED visits for schizophrenia spectrum disorders.
16 sychiatric ED visits, with 37 815 visits for schizophrenia spectrum disorders.
17 n of Diseases codes for bipolar disorder and schizophrenia spectrum disorders.
18 dded to clozapine or olanzapine treatment of schizophrenia spectrum disorders.
19 he mechanisms underlying the pathogenesis of schizophrenia spectrum disorders.
20 heritability and has been found deficient in schizophrenia spectrum disorders.
21 veness study for patients with first-episode schizophrenia spectrum disorders.
22 od, 30 556 people developed schizophrenia or schizophrenia spectrum disorders.
23 iated with higher rates of schizophrenia and schizophrenia spectrum disorders.
24 ective disorders, personality disorders, and schizophrenia spectrum disorders.
25 otype for investigating the genetic basis of schizophrenia spectrum disorders.
26 obtained for 119 patients with recent-onset schizophrenia spectrum disorders.
27 sers, adds support for a cannabinoid link to schizophrenia spectrum disorders.
28 th the levels of glutamate and liability for schizophrenia spectrum disorders.
29 s risperidone in patients with first-episode schizophrenia spectrum disorders.
30 a larger study investigating early signs of schizophrenia spectrum disorders.
31 ced psychosis converted to either bipolar or schizophrenia-spectrum disorders.
32 educe medication nonadherence and relapse in schizophrenia-spectrum disorders.
33 ved outcome for Mexican American adults with schizophrenia-spectrum disorders.
34 tcomes that were rare among individuals with schizophrenia spectrum disorders (0% and 0.6%, respectiv
35 ifference, 4%; 95% CI, 3%-5%; P < .001), and schizophrenia spectrum disorder (103 [3%] vs 36 [1%]; di
37 = 9.6 [5.9 to 15.6], p < 0.001) and lifetime schizophrenia-spectrum disorders (11.0 [7.1 to 17.0], p
39 t 21.7% (95% CI 13.1% to 31.7%), followed by schizophrenia spectrum disorders (12.4% [95% CI 9.5% to
40 olar disorder (5.5% vs. 2.3%; P < .001), and schizophrenia spectrum disorders (2.3% vs. 0.9%; P < .00
41 ion diagnoses before their testing date: (1) schizophrenia spectrum disorders, (2) mood disorders, an
42 eline, the diagnostic distribution was 29.6% schizophrenia spectrum disorders, 21.1% bipolar disorder
43 ia had a significantly higher morbid risk of schizophrenia spectrum disorders (24.74%) than parents o
44 ents with first-episode psychosis (20 with a schizophrenia spectrum disorder, 26 with bipolar disorde
45 NTS Volunteer sample of 335 individuals with schizophrenia spectrum disorders (306 with core schizoph
46 repeated on a replication sample (N=108; 32 schizophrenia spectrum disorder, 37 euthymic bipolar dis
48 ditional analysis including 78 patients with schizophrenia spectrum disorders (64 males, 14 females)
50 mine whether monthly counts of ED visits for schizophrenia spectrum disorders across 5 University of
52 associated with increased risk of developing schizophrenia spectrum disorder, adult depression, and a
53 spectrum disorders were also associated with schizophrenia spectrum disorders, affective disorders, a
54 ic (DZ) proband pairs con- or discordant for schizophrenia spectrum disorders, along with healthy con
55 nce use and addiction, bipolar disorder, and schizophrenia spectrum disorder among adults with strabi
57 al records) was 56.4% (95% CI 55.4-57.4) for schizophrenia spectrum disorder and 49.7% (95% CI 48.1-5
58 he Schizophrenia(s) study (N=179; 109 with a schizophrenia spectrum disorder and 70 healthy control p
60 The study was completed by 24 patients with schizophrenia spectrum disorders and 30 healthy control
61 s study, we obtained CSF in 32 patients with schizophrenia spectrum disorders and 32 healthy voluntee
63 in a group of age-matched participants with schizophrenia spectrum disorders and a group of age-matc
64 groups, were used to identify ED visits for schizophrenia spectrum disorders and all other psychiatr
65 ng individuals were aged 18 to 65 years with schizophrenia spectrum disorders and clozapine or olanza
66 icantly increased IRRs for schizophrenia and schizophrenia spectrum disorders and had similar risk ma
67 for violence, respectively, in persons with schizophrenia spectrum disorders and in samples of both
68 studies were less than 1 in 20 in women with schizophrenia spectrum disorders and less than 1 in 4 in
69 ments had higher familial loading scores for schizophrenia spectrum disorders and more obstetrical co
70 for major depressive disorder (MDD), mania, schizophrenia spectrum disorders and other diagnoses.
71 prevalence of clinician-assessed SCID-based schizophrenia spectrum disorders and positive psychotic
72 social functioning from 485 respondents with schizophrenia spectrum disorders and psychotic mood diso
74 play a role in regulating the expression of schizophrenia spectrum disorders and that targeting the
75 he emergence of suicidality in patients with schizophrenia spectrum disorders and that the deficit sy
76 ed in patients with first episodes of DSM-IV schizophrenia spectrum disorders and whether shorted dur
77 th the risk of adult schizophrenia and other schizophrenia spectrum disorders and with the risk of sc
78 at included >=80% of patients diagnosed with schizophrenia-spectrum disorders and used a validated sc
79 : presence or absence of major depression, a schizophrenia spectrum disorder, and bipolar disorder.
80 with anti-NMDAR encephalitis, 27 (33%) with schizophrenia spectrum disorders, and 27 (33%) healthy p
81 disorder, substance use disorders, insomnia, schizophrenia spectrum disorders, and bipolar disorder.
82 l personality disorder, the prototype of the schizophrenia spectrum disorders, and chronic schizophre
83 Rates of obstetric complications, familial schizophrenia spectrum disorders, and familial eye track
84 typal personality traits are associated with schizophrenia spectrum disorders, and individuals with s
85 al features of this stage, similarities with schizophrenia spectrum disorders, and the factors that p
86 oses-albeit overall worse social outcomes in schizophrenia spectrum disorders-and show remarkably sta
87 ch was significantly higher in patients with schizophrenia spectrum disorders (aOR, 5.0; 95% CI, 3.0-
88 reases in thalamic glutamate levels found in schizophrenia spectrum disorders are explained by geneti
90 st lifetime diagnosis of schizophrenia and a schizophrenia spectrum disorder assigned by a psychiatri
91 144 healthy volunteers and 293 patients with schizophrenia spectrum disorder at a tertiary care unive
92 , 11.7-129.3 additional visits; P = .02) for schizophrenia spectrum disorders at 1 month and 74.9 add
93 EIS vs TAU among individuals with diagnosed schizophrenia spectrum disorders at 20 years were found.
94 controls and 434 individuals diagnosed with schizophrenia-spectrum disorders at different illness st
95 ersistent distressing PLEs with cortical RVI-schizophrenia spectrum disorders (beta estimate, 1.055;
96 tal illness (SMI), defined as a diagnosis of schizophrenia spectrum disorder, bipolar disorder, or di
97 lowing RVI cortical and subcortical metrics: schizophrenia spectrum disorders, bipolar disorder, majo
98 the cornerstone of maintenance treatment in schizophrenia spectrum disorders, but it is unclear whic
99 th anti-NMDAR encephalitis and in those with schizophrenia spectrum disorders, but only those in indi
100 is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based rec
101 t outcomes was increased in individuals with schizophrenia spectrum disorders compared with community
102 arly intervention services for first-episode schizophrenia spectrum disorders compared with standard
103 have an estimated 25-fold increased risk for schizophrenia spectrum disorders, compared to individual
104 five healthy subjects and 62 patients with a schizophrenia spectrum disorder completed a battery of t
105 est choices for the maintenance treatment of schizophrenia-spectrum disorders, considering that both
106 ce perpetration outcomes in individuals with schizophrenia spectrum disorders contribute to morbidity
107 els and whether a potential association with schizophrenia spectrum disorders could be explained by g
108 during WM performance among individuals with schizophrenia-spectrum disorders could enhance our under
109 aged 12-17 years with a diagnosis of ICD-10 schizophrenia-spectrum disorder, delusional disorder, or
110 nia spectrum disorders, and individuals with schizophrenia spectrum disorders demonstrate increased d
111 large New York medical system, adults with a schizophrenia spectrum disorder diagnosis were associate
115 tivity (e.g., proportion of individuals with schizophrenia spectrum disorders (F20-29) who received a
117 tors for schizophrenia (familial loading for schizophrenia spectrum disorders, familial eye-tracking
118 -analyses of studies including patients with schizophrenia spectrum disorders, first-episode psychosi
119 The authors assessed 229 patients with a schizophrenia spectrum disorder five times: during the f
120 ehavior disorders; several antipsychotics in schizophrenia spectrum disorders; fluoxetine, the combin
121 depression, psychosis, bipolar disorder, and schizophrenia spectrum disorders for people who are inca
122 aged 16 to 65 years who were diagnosed with schizophrenia spectrum disorder from January 1, 2006, to
123 xiety disorders, bipolar disorder/mania, and schizophrenia spectrum disorders from any time before th
124 odalities reliably differentiated those with schizophrenia spectrum disorders from controls (OR = 2.6
125 development of psychosis, schizophrenia, and schizophrenia spectrum disorders, generating the hypothe
128 Underrepresented (ineligible) patients with schizophrenia spectrum disorders have moderately higher
129 rders, including psychopathy, and autism and schizophrenia spectrum disorders, have been linked with
130 These findings suggest that in patients with schizophrenia spectrum disorders, hippocampal volume is
131 havior among patients with schizophrenia and schizophrenia spectrum disorders in a long-term follow-u
132 evaluated machine learning classification of schizophrenia spectrum disorders in comparison to health
133 reatment of, and service issues relating to, schizophrenia spectrum disorders in people with intellec
134 he number of published studies investigating schizophrenia spectrum disorders in people with intellec
135 o examine most recently published studies of schizophrenia spectrum disorders in people with intellec
136 prenatal nutrition has been associated with schizophrenia spectrum disorders in the Netherlands and
138 o group membership, and the morbid risks for schizophrenia spectrum disorders in the three groups wer
139 , evidence pertaining to temporal changes in schizophrenia spectrum disorders in the US following the
141 itive remediation in patients diagnosed with schizophrenia spectrum disorders in which follow-up asse
143 ition (sensorimotor gating) in patients with schizophrenia spectrum disorders, including subjects wit
144 ophrenia (IRR = 4.31; 95% CI, 2.72-6.43) and schizophrenia spectrum disorders (IRR = 3.10; 95% CI, 2.
145 ophrenia (IRR = 6.90; 95% CI, 6.25-7.60) and schizophrenia spectrum disorders (IRR = 5.77; 95% CI, 5.
147 ms, 10th Revision, codes F00-F99), including schizophrenia-spectrum disorders, mood disorders, neurot
148 64 birth cohort members diagnosed as having schizophrenia spectrum disorders (mostly schizophrenia a
149 Cases (N=59) were subjects diagnosed with schizophrenia spectrum disorders (mostly schizophrenia a
150 181) and individuals with DSM-IV -diagnosed schizophrenia spectrum disorder (n = 94), bipolar spectr
152 nal Patient Register who were diagnosed with schizophrenia spectrum disorders (n = 34903) and bipolar
153 sample of general psychiatric patients with schizophrenia spectrum disorders (N = 637) to evaluate t
155 e high burden of substance use disorders and schizophrenia spectrum disorders need particular attenti
156 s from substance-induced psychosis to either schizophrenia spectrum disorder or bipolar disorder.
157 birth cohort, had not been diagnosed with a schizophrenia spectrum disorder or major affective disor
158 an increased risk of death in patients with schizophrenia spectrum disorders or bipolar disorders.
159 te the relationship between malnutrition and schizophrenia spectrum disorders or whether this associa
161 disorder (OR: 2.23; 95% CI: 2.04-2.44), and schizophrenia spectrum disorder (OR: 2.48; 95% CI: 2.17-
162 oportions of RCT-ineligible individuals with schizophrenia spectrum disorders owing to any and specif
165 and positively correlated with liability for schizophrenia spectrum disorders (phenotypic correlation
166 .5 years (k = 58, median = 25, IQR = 20-41), schizophrenia-spectrum disorders/primary psychotic state
167 n risk suggests that OCD, schizophrenia, and schizophrenia spectrum disorders probably lay on a commo
170 out efficacy and safety of antipsychotics in schizophrenia spectrum disorders relies on randomized cl
171 over 4 decades (N = 51 309 individuals with schizophrenia spectrum disorders; reported mean age of 2
173 between perimenopause and incidence rates of schizophrenia spectrum disorders (RR of 0.95 (95% CI 0.4
174 k ratio [RRR], 6.17; 95% CI, 3.19-11.96) and schizophrenia spectrum disorders (RRR, 2.98; 95% CI, 2.1
175 d via nasal spray to male individuals with a schizophrenia spectrum disorder (schizophrenia and schiz
176 ssive disorder (MDD), bipolar disorder (BD), schizophrenia spectrum disorders (SCZ), and population c
177 ny differences, autism spectrum disorder and schizophrenia spectrum disorder share environmental risk
178 tric, and early-life environmental risks for schizophrenia spectrum disorder (SSD) alter normal cereb
179 isorder, major depressive disorder (MDD), or schizophrenia spectrum disorder (SSD) and (2) a subcohor
180 in the anterior cingulate cortex (ACC) in 59 schizophrenia spectrum disorder (SSD) patients and 69 ma
183 s significantly associated with diagnoses of schizophrenia spectrum disorder (SSD; adjusted odds rati
185 y including Autism Spectrum Disorders (ASD), Schizophrenia Spectrum Disorders (SSD), and Intellectual
187 ely replicated neuropathological features in schizophrenia-spectrum disorder (SSD), although their bi
188 ric and neonatal complications in women with schizophrenia-spectrum disorder (SSD), but most inadequa
189 velocity and has been extensively studied in schizophrenia-spectrum disorders (SSD), less is known ab
191 ts are a substantial part of the symptoms of schizophrenia spectrum disorders (SSDs) and contribute h
192 ethnoracial disparities in the prevalence of schizophrenia spectrum disorders (SSDs) and positive psy
193 l brain alterations that are associated with schizophrenia spectrum disorders (SSDs) are already pres
195 sment tools to explore self-disorders within schizophrenia spectrum disorders (SSDs) were included.
199 er (BCB) disruption could be key elements in schizophrenia-spectrum disorders(SSDs) etiology and symp
200 nsomnia (g = 0.35, 95% CI [0.28, 0.42]), and schizophrenia spectrum disorders (standardized mean chan
201 al disabilities, mood and anxiety disorders, schizophrenia spectrum disorders, substance use disorder
202 n parents (ie, depression, bipolar disorder, schizophrenia-spectrum disorders, substance abuse, and a
203 ards are hypothesized to be core features of schizophrenia spectrum disorders (SZ) and bipolar disord
204 in patients with psychotic illnesses [i.e., schizophrenia spectrum disorders (SZ) and bipolar I diso
205 of both patient groups had a greater risk of schizophrenia spectrum disorders than did parents of com
206 the mothers of offspring who later developed schizophrenia spectrum disorders than in matched compari
207 od-onset schizophrenia have a higher rate of schizophrenia spectrum disorders than parents of patient
208 Schizotypal personality disorder (SPD) is a schizophrenia-spectrum disorder that is biologically rel
209 had a comparator (all involving adults with schizophrenia spectrum disorders), three used haloperido
210 cally used in RCTs for relapse prevention in schizophrenia spectrum disorders to real-world populatio
211 ardiometabolic disturbances in patients with schizophrenia spectrum disorders treated with clozapine
213 ed registers to investigate the incidence of schizophrenia spectrum disorders, unipolar depression, b
215 ion rate from substance-induced psychosis to schizophrenia spectrum disorder was 27.6% (95% CI=25.6-2
216 cal risk factors, a premorbid diagnosis of a schizophrenia spectrum disorder was significantly associ
217 e of bipolar disorder was 1.7% (1.0-2.6) and schizophrenia spectrum disorders was 3.6% (1.3-7.1).
218 ic monthly mean (SD) number of ED visits for schizophrenia spectrum disorders was 519.9 (38.1), which
219 most common trajectory for individuals with schizophrenia spectrum disorders was no remission and no
223 on rates from substance-induced psychosis to schizophrenia spectrum disorder were six times higher th
225 sal ganglia volumes of 23 male patients with schizophrenia spectrum disorders were measured from manu
226 e were no diagnostic differences except that schizophrenia spectrum disorders were more common among
228 ter IL-8 levels in mothers of offspring with schizophrenia spectrum disorders were significantly high
230 d voices were compared with 21 patients with schizophrenia spectrum disorders who did not report voic
231 reducing psychiatric symptoms in people with schizophrenia spectrum disorders who had chosen not to t
232 e and acceptable alternative for people with schizophrenia spectrum disorders who have chosen not to
236 control condition in patients diagnosed with schizophrenia spectrum disorders (with an unrestricted c
237 ly increased risk of schizophrenia and other schizophrenia spectrum disorders, with adjustment for ma
238 study found a 15% increase in ED visits for schizophrenia spectrum disorders within 3 months after t
239 A total of 20 060 individuals (79%) with schizophrenia spectrum disorders would be ineligible for